Elivaldogene autotemcel
Explore a selection of our essential drug information below, or:
Identification
- Summary
Elivaldogene autotemcel is a gene replacement therapy for treating early cerebral adrenoleukodystrophy comprising autologous hematopoietic stem cells transduced with a viral vector encoding ABCD1 complementary DNA for human adrenoleukodystrophy protein.
- Brand Names
- Skysona
- Generic Name
- Elivaldogene autotemcel
- DrugBank Accession Number
- DB16746
- Background
Elivaldogene autotemcel is a gene therapy consisting of genetically modified autologous cells. It is used to provide functional copies of human adrenoleukodystrophy protein (ALDP) in patients with adrenoleukodystrophy,4 an X-linked genetic disorder characterized by missing or non-functional ABCD1 gene that codes for ALDP.1 ALDP is a key protein that normally breaks down fatty substances in the body called very long-chain fatty acids (VLCFAs). Without sufficient levels of functional ALDP, VLCFAs accumulate in the body leading to inflammation and destruction of myelin, which is an insulating layer and essential component of nerves.5
Cerebral adrenoleukodystrophy is an inflammatory cerebral phenotype that more commonly affects young men: it is associated with progressive brain function loss and poor survival rates without treatment. Allogeneic hematopoietic stem-cell transplantation has been the primary treatment option; however, it is associated with a risk of graft failure and graft-versus-host disease (GVHD), calling for alternative treatment options. Gene therapy with autologous hematopoietic stem cells was introduced and investigated as a possible treatment for patients with adrenoleukodystrophy.1 Elivaldogene autotemcel works by delivering genes into the patient's body to produce functional ALDPs. It was approved by the European Commission in July 2021 under the market name Skysona, and was later withdrawn in November 2021 at the request of the marketing-authorization holder.5 In September 2022, Skysona was approved by the FDA.6
- Type
- Biotech
- Groups
- Approved
- Biologic Classification
- Gene Therapies
Other gene therapies - Synonyms
- eli-cel
Pharmacology
- Indication
Elivaldogene autotemcel is indicated to slow the progression of neurologic dysfunction in boys 4-17 years of age with early, active cerebral adrenoleukodystrophy (CALD). Early, active CALD refers to asymptomatic or mildly symptomatic (neurologic function score, NFS ≤ 1) boys who have gadolinium enhancement on brain magnetic resonance imaging (MRI) and Loes scores of 0.5-9.6
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Management of Neurologic dysfunction •••••••••••• ••••••• ••••• •••••••• •••••••••••••••••••• •••••• •••••••••• •••••••••• - Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Elivaldogene autotemcel works to restore missing or low levels of adrenoleukodystrophy protein (ALDP) in patients adrenoleukodystrophy by delivering copies of genes that code for ALDP. While the drug aims to stabilize the disease by slowing down its progression, elivaldogene autotemcel is not expected to affect other manifestations of adrenoleukodystrophy such as adrenal insufficiency. The clinical impact of elivaldogene autotemcel on adrenomyeloneuropathy has not been studied.4
In one clinical study (Study ALD-102), all patients produced ALDP in CD14+ peripheral blood cells within one month of treatment and had a median CD14+ ALDP+ of 29.50%, indicating early expression of the transgene. At six months of follow-up, CD14+ ALDP+ cells slightly declined after drug infusion and stabilized by approximately six months of treatment.4 Elivaldogene autotemcel is typically not associated with treatment-related death or graft-versus-host disease.1
- Mechanism of action
Adrenoleukodystrophy protein (ALDP or ABCD1) is a half ATP-binding cassette (ABC) transporter localized in the peroxisomal membrane. It plays a role in peroxisomal beta-oxidation and the breakdown of very long-chain fatty acids (VLCFAs) in organs.3 Adrenoleukodystrophy is an X-linked genetic disorder caused by the mutations in the ABCD1 gene that encodes ALDP, leading to impaired production of ALDP.1 The lack of functional ALDP leads to increased intracellular concentrations of VLCFAs and incorporation of VLCFAs into different complex lipids, including myelin sheaths that are particularly vulnerable to inflammation. VLCFA-induced myelin membrane instability leads to a pro-inflammatory brain environment, causing progressive, inflammatory cerebral demyelination and axonopathy. These pathological events can also be accompanied by oxidative stress and energy shortage in axons as well as non-cell-autonomous processes involving axon–glial interactions.2
Elivaldogene autotemcel consists of autologous CD34+ hematopoietic stem cells transduced ex vivo with a lentiviral vector encoding ABCD1 complementary DNA (cDNA). Following administration of elivaldogene autotemcel, autologous CD34+ hematopoietic stem cells engraft in the bone marrow and differentiate into various cell types, including monocytes (CD14+) that migrate to the brain, where they can further differentiate into macrophages and cerebral microglia that can produce functional ALDP. Functional ALDPs can promote the local degradation of VLCFAs in the brain, stabilizing the course of the disease to prevent further inflammation and demyelination. Following successful engraftment with genetically modified cells, the expression of ALDP is expected to be life-long.4
- Absorption
As elivaldogene autotemcel is a gene therapy comprising autologous cells which have been modified ex vivo, conventional studies on pharmacokinetic properties are not applicable.4
- Volume of distribution
As elivaldogene autotemcel is a gene therapy comprising autologous cells which have been modified ex vivo, conventional studies on pharmacokinetic properties are not applicable.4
- Protein binding
As elivaldogene autotemcel is a gene therapy comprising autologous cells which have been modified ex vivo, conventional studies on pharmacokinetic properties are not applicable.4
- Metabolism
As elivaldogene autotemcel is a gene therapy comprising autologous cells which have been modified ex vivo, conventional studies on pharmacokinetic properties are not applicable.4
- Route of elimination
As elivaldogene autotemcel is a gene therapy comprising autologous cells which have been modified ex vivo, conventional studies on pharmacokinetic properties are not applicable.4
- Half-life
As elivaldogene autotemcel is a gene therapy comprising autologous cells which have been modified ex vivo, conventional studies on pharmacokinetic properties are not applicable.4
- Clearance
As elivaldogene autotemcel is a gene therapy comprising autologous cells which have been modified ex vivo, conventional studies on pharmacokinetic properties are not applicable.4
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
There is no scientific or clinical data regarding the LD50 or overdose of elivaldogene autotemcel.
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAdenovirus type 7 vaccine live The risk or severity of adverse effects can be increased when Elivaldogene autotemcel is combined with Adenovirus type 7 vaccine live. Amprenavir The therapeutic efficacy of Elivaldogene autotemcel can be decreased when used in combination with Amprenavir. Anthrax vaccine The risk or severity of adverse effects can be increased when Elivaldogene autotemcel is combined with Anthrax vaccine. Asunaprevir The therapeutic efficacy of Elivaldogene autotemcel can be decreased when used in combination with Asunaprevir. Atazanavir The therapeutic efficacy of Elivaldogene autotemcel can be decreased when used in combination with Atazanavir. - Food Interactions
- No interactions found.
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- International/Other Brands
- Skysona (Bluebird Bio)
- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Skysona Suspension 30000000 1/1 Intravenous bluebird bio, Inc. 2022-09-16 Not applicable US
Categories
- ATC Codes
- A16AX21 — Elivaldogene autotemcel
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Humans
Chemical Identifiers
- UNII
- KUM75TD6SG
- CAS number
- Not Available
References
- General References
- Eichler F, Duncan C, Musolino PL, Orchard PJ, De Oliveira S, Thrasher AJ, Armant M, Dansereau C, Lund TC, Miller WP, Raymond GV, Sankar R, Shah AJ, Sevin C, Gaspar HB, Gissen P, Amartino H, Bratkovic D, Smith NJC, Paker AM, Shamir E, O'Meara T, Davidson D, Aubourg P, Williams DA: Hematopoietic Stem-Cell Gene Therapy for Cerebral Adrenoleukodystrophy. N Engl J Med. 2017 Oct 26;377(17):1630-1638. doi: 10.1056/NEJMoa1700554. Epub 2017 Oct 4. [Article]
- Berger J, Forss-Petter S, Eichler FS: Pathophysiology of X-linked adrenoleukodystrophy. Biochimie. 2014 Mar;98:135-42. doi: 10.1016/j.biochi.2013.11.023. Epub 2013 Dec 4. [Article]
- van Roermund CW, Visser WF, Ijlst L, van Cruchten A, Boek M, Kulik W, Waterham HR, Wanders RJ: The human peroxisomal ABC half transporter ALDP functions as a homodimer and accepts acyl-CoA esters. FASEB J. 2008 Dec;22(12):4201-8. doi: 10.1096/fj.08-110866. Epub 2008 Aug 29. [Article]
- EMA Summary of Product Characteristics: Skyvona (elivaldogene autotemcel) for intravenous infusion [Link]
- European Medicines Agency: Skysona (elivaldogene autotemcel) [Link]
- FDA Approved Drug Products: SKYSONA (elivaldogene autotemcel) suspension for intravenous infusion [Link]
- External Links
- KEGG Drug
- D12150
- 2612527
- Wikipedia
- Elivaldogene_autotemcel
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Suspension Intravenous 30000000 1/1 - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Liquid
- Experimental Properties
- Not Available
Drug created at December 20, 2021 15:20 / Updated at August 10, 2024 03:44